Abstract
A HIV Vaccine, particularly that based on recombinant proteins and plasmid DNA, is likely to be less reactogenic than traditional vaccines, but also less immunogenic. Therefore, there is an urgent need for the development of new and improved adjuvants and delivery system for combination with HIV vaccine antigens. Adjuvants can be broadly separated into two classes, based on their principal mechanisms of action; “vaccine delivery systems” and “immunostimulatory adjuvants”. Vaccine delivery systems are generally particulate formulations e.g. emulsions, microparticles, iscoms and liposomes, and mainly function to target associated antigens into antigen presenting cells (APC). In contrast, immunostimulatory adjuvants are predominantly derived from pathogens and often represent pathogen associated molecular patterns (PAMP) e.g. LPS, MPL, CpG DNA, which activate cells of the innate immune system. The discovery of more potent adjuvants may allow the development of prophylactic and therapeutic vaccines against HIV. In addition, new adjuvants may also allow vaccines to be delivered mucosally.
Keywords: hiv vaccine adjuvants, immunostimulators, vaccine delivery systems, microparticles, emulsions
Current HIV Research
Title: Advances in Vaccine Adjuvants For Infectious Diseases
Volume: 1 Issue: 3
Author(s): Manmohan Singh and Indresh Srivastava
Affiliation:
Keywords: hiv vaccine adjuvants, immunostimulators, vaccine delivery systems, microparticles, emulsions
Abstract: A HIV Vaccine, particularly that based on recombinant proteins and plasmid DNA, is likely to be less reactogenic than traditional vaccines, but also less immunogenic. Therefore, there is an urgent need for the development of new and improved adjuvants and delivery system for combination with HIV vaccine antigens. Adjuvants can be broadly separated into two classes, based on their principal mechanisms of action; “vaccine delivery systems” and “immunostimulatory adjuvants”. Vaccine delivery systems are generally particulate formulations e.g. emulsions, microparticles, iscoms and liposomes, and mainly function to target associated antigens into antigen presenting cells (APC). In contrast, immunostimulatory adjuvants are predominantly derived from pathogens and often represent pathogen associated molecular patterns (PAMP) e.g. LPS, MPL, CpG DNA, which activate cells of the innate immune system. The discovery of more potent adjuvants may allow the development of prophylactic and therapeutic vaccines against HIV. In addition, new adjuvants may also allow vaccines to be delivered mucosally.
Export Options
About this article
Cite this article as:
Singh Manmohan and Srivastava Indresh, Advances in Vaccine Adjuvants For Infectious Diseases, Current HIV Research 2003; 1 (3) . https://dx.doi.org/10.2174/1570162033485195
DOI https://dx.doi.org/10.2174/1570162033485195 |
Print ISSN 1570-162X |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4251 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Advances in the Membrane Receptor Initiated Vitamin D Signaling of Calcium and Phosphate Transport Across Intestinal and Kidney Epithelia
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) The Role of Melatonin in Multiple Sclerosis, Huntington's Disease and Cerebral Ischemia
CNS & Neurological Disorders - Drug Targets RAN GTPase as a Target for Cancer Therapy: Ran Binding Proteins
Current Molecular Medicine An overview of ABC and SLC Drug Transporter Gene Regulation
Current Drug Metabolism Antigenic Peptide Vaccination: Provoking Immune Response and Clinical Benefit for Cancer
Current Immunology Reviews (Discontinued) Optimizing Gene Silencing Strategies for Pancreatic Cancer
Current Cancer Therapy Reviews Emerging Technologies for Fertility Preservation in Female Patients
Current Women`s Health Reviews Chemoprevention of Colorectal Cancer: Progress or Pipedream?
Current Cancer Therapy Reviews Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled
Current Molecular Pharmacology Genetic and Epigenetic Studies for Determining Molecular Targets of Natural Product Anticancer Agents
Current Cancer Drug Targets Structure-Activity Relationships of Flavonoids
Current Organic Chemistry PD1 and PD-L1 Inhibitors for the Treatment of Kidney Cancer: The Role of PD-L1 Assay
Current Drug Targets Apoptosis Induction by Thalidomide: Critical for Limb Teratogenicity but Therapeutic Potential in Idiopathic Pulmonary Fibrosis?
Current Molecular Pharmacology Cancer-Type Organic Anion Transporting Polypeptide 1B3: Current Knowledge of the Gene Structure, Expression Profile, Functional Implications and Future Perspectives
Current Drug Metabolism Multidrug Resistance Through the Spectacle of P-Glycoprotein
Current Cancer Drug Targets Silibinin – A Promising New Treatment for Cancer
Anti-Cancer Agents in Medicinal Chemistry Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles
Current Gene Therapy Human Leukemia and Lymphoma Cell Lines as Models and Resources
Current Medicinal Chemistry Targeting Angiogenesis in Renal Cell Carcinoma
Current Cancer Drug Targets Proteomics-Based Characterization of the Effects of MMP14 on the Protein Content of Exosomes from Corneal Fibroblasts
Protein & Peptide Letters